Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 11:53AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.35 Insider Own40.81% Shs Outstand49.18M Perf Week-0.29%
Market Cap460.26M Forward P/E- EPS next Y-1.91 Insider Trans20.85% Shs Float41.71M Perf Month-11.62%
Income-116.20M PEG- EPS next Q-0.45 Inst Own62.35% Short Float16.62% Perf Quarter-31.47%
Sales0.00M P/S- EPS this Y15.88% Inst Trans-4.90% Short Ratio6.79 Perf Half Y150.24%
Book/sh6.72 P/B0.97 EPS next Y5.46% ROA-22.45% Short Interest6.93M Perf Year43.55%
Cash/sh6.21 P/C1.05 EPS next 5Y- ROE-28.33% 52W Range1.28 - 16.24 Perf YTD-1.04%
Dividend Est.- P/FCF- EPS past 5Y-209.81% ROI-20.95% 52W High-59.78% Beta0.87
Dividend TTM- Quick Ratio19.95 Sales past 5Y-39.65% Gross Margin- 52W Low410.26% ATR (14)0.62
Dividend Ex-Date- Current Ratio19.95 EPS Y/Y TTM5.77% Oper. Margin0.00% RSI (14)39.29 Volatility7.94% 8.34%
Employees150 Debt/Eq0.18 Sales Y/Y TTM- Profit Margin- Recom1.11 Target Price19.29
Option/ShortYes / Yes LT Debt/Eq0.17 EPS Q/Q7.54% Payout- Rel Volume0.19 Prev Close6.73
Sales Surprise- EPS Surprise-6.40% Sales Q/Q- EarningsMay 09 AMC Avg Volume1.02M Price6.53
SMA20-4.92% SMA50-25.87% SMA20014.07% Trades Volume79,080 Change-2.95%
Date Action Analyst Rating Change Price Target Change
Mar-22-24Downgrade Raymond James Strong Buy → Outperform $13 → $16
Dec-22-22Downgrade Oppenheimer Outperform → Perform
Oct-10-22Initiated Canaccord Genuity Buy $25
Jul-28-22Initiated Needham Buy $26
Jul-18-22Initiated SVB Leerink Outperform $30
Mar-11-22Initiated Raymond James Outperform $17
Mar-08-22Initiated H.C. Wainwright Buy $25
Jan-06-22Initiated William Blair Outperform
Nov-18-21Initiated SMBC Nikko Outperform $50
Jul-16-21Initiated Oppenheimer Outperform $75
May-10-24 02:56PM
May-09-24 10:57PM
May-07-24 06:30AM
Apr-03-24 04:02PM
04:06PM Loading…
Mar-25-24 04:06PM
Mar-23-24 05:31AM
Mar-22-24 04:03PM
Mar-21-24 10:54PM
Mar-19-24 07:29AM
Feb-29-24 06:30AM
Feb-28-24 08:01AM
04:19PM Loading…
Feb-20-24 04:19PM
Feb-08-24 09:32AM
Feb-06-24 12:50PM
Feb-05-24 12:41PM
Feb-04-24 08:00AM
Jan-09-24 10:25AM
Dec-09-23 08:31PM
Dec-08-23 12:00PM
Nov-14-23 03:56PM
Nov-09-23 04:02PM
Nov-07-23 08:02AM
Oct-25-23 02:06PM
Oct-18-23 10:47AM
08:17PM Loading…
Oct-17-23 08:17PM
Oct-16-23 04:01PM
Oct-02-23 03:07PM
Aug-10-23 07:01AM
Aug-03-23 08:02AM
Jul-31-23 06:30PM
Jul-05-23 04:02PM
Jun-28-23 09:35AM
Jun-27-23 01:02PM
Jun-26-23 04:01PM
Jun-15-23 09:55AM
Jun-10-23 10:47AM
May-11-23 04:02PM
May-09-23 07:15AM
May-07-23 12:50PM
Apr-17-23 05:01PM
Apr-12-23 09:06PM
Apr-11-23 09:46AM
Mar-30-23 04:01PM
Mar-16-23 04:01PM
Feb-17-23 05:35AM
Feb-09-23 08:02AM
Jan-09-23 04:30PM
Dec-05-22 07:02AM
Dec-02-22 04:02PM
Nov-09-22 04:02PM
Nov-07-22 08:52AM
Nov-02-22 08:02AM
Sep-24-22 09:34AM
Sep-23-22 07:30AM
Aug-11-22 04:02PM
Aug-10-22 08:42AM
Aug-07-22 06:15AM
Jul-25-22 04:31PM
Jul-18-22 02:46PM
Jun-14-22 07:14AM
Jun-07-22 09:55AM
May-31-22 07:02AM
May-18-22 12:00PM
May-16-22 04:02PM
May-12-22 04:02PM
May-09-22 04:02PM
May-06-22 05:30PM
May-02-22 10:45AM
Apr-28-22 04:01PM
Apr-25-22 11:19PM
Apr-22-22 04:10PM
Apr-17-22 08:54AM
Apr-08-22 01:25PM
Apr-04-22 12:00PM
Mar-29-22 08:02AM
Mar-22-22 10:00AM
Mar-17-22 04:02PM
Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm's product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RA CAPITAL MANAGEMENT, L.P.DirectorMar 27 '24Buy10.003,000,00030,000,00010,050,818Mar 29 05:38 PM
George SimeonDirectorMar 27 '24Buy10.002,000,00020,000,0001,548,341Mar 28 04:30 PM
Brandenberger RalphChief Technical OfficerMar 01 '24Option Exercise3.896,76326,30888,339Mar 05 04:26 PM
Brandenberger RalphChief Technical OfficerMar 01 '24Sale12.518,367104,67179,972Mar 05 04:26 PM
Trager JamesChief Scientific OfficerFeb 12 '24Sale12.004,14349,716149,415Feb 14 09:12 PM
HASTINGS PAUL JChief Executive OfficerJan 16 '24Sale8.749,69784,752390,507Jan 18 04:40 PM
Trager JamesChief Scientific OfficerJan 16 '24Sale8.744,56039,854153,558Jan 18 04:43 PM
Hager Alicia J.Chief Legal OfficerJan 16 '24Sale8.744,55439,802107,942Jan 18 04:38 PM
Shook DavidChief Medical OfficerJan 16 '24Sale8.743,55231,044114,980Jan 18 04:45 PM
Brandenberger RalphChief Technical OfficerJan 16 '24Sale8.742,51221,95581,576Jan 18 04:40 PM
Shook DavidChief Medical OfficerAug 21 '23Sale1.831,3312,43660,532Aug 23 04:11 PM
HASTINGS PAUL JChief Executive OfficerJun 20 '23Sale4.851,7048,264313,402Jun 22 04:20 PM
Hager Alicia J.Chief Legal OfficerJun 20 '23Sale4.857013,40056,496Jun 22 04:23 PM
Mahmood NadirSee RemarksJun 20 '23Sale4.855262,55185,776Jun 22 04:21 PM
Trager JamesChief Scientific OfficerJun 20 '23Sale4.854392,129100,118Jun 22 04:26 PM
Shook DavidChief Medical OfficerJun 20 '23Sale4.854392,12961,863Jun 22 04:22 PM
Brandenberger RalphChief Technical OfficerJun 20 '23Sale4.852211,07228,088Jun 22 04:25 PM